Francis Spinale to Humans
This is a "connection" page, showing publications Francis Spinale has written about Humans.
Connection Strength
1.212
-
Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. Int Heart J. 2021 Sep 30; 62(5):1096-1105.
Score: 0.030
-
Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post-Myocardial Infarction Remodeling. J Pharmacol Exp Ther. 2020 11; 375(2):296-307.
Score: 0.028
-
Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. J Card Fail. 2020 Oct; 26(10):876-884.
Score: 0.027
-
Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype. Nat Rev Cardiol. 2020 08; 17(8):523-531.
Score: 0.026
-
Common pathways and communication between the brain and heart: connecting post-traumatic stress disorder and heart failure. Stress. 2019 09; 22(5):530-547.
Score: 0.025
-
Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. JAMA Cardiol. 2018 12 01; 3(12):1232-1243.
Score: 0.024
-
Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
Score: 0.024
-
Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy. Am J Physiol Heart Circ Physiol. 2018 11 01; 315(5):H1443-H1452.
Score: 0.024
-
Cardiovascular Risk and Matrix Metalloproteinase Polymorphisms: Not Just a Simple Substitution. Circ Cardiovasc Genet. 2017 12; 10(6):e001958.
Score: 0.023
-
In vivo assessment of regional mechanics post-myocardial infarction: A focus on the road ahead. J Appl Physiol (1985). 2017 Oct 01; 123(4):728-745.
Score: 0.022
-
Crossing Into the Next Frontier of Cardiac Extracellular Matrix Research. Circ Res. 2016 10 28; 119(10):1040-1045.
Score: 0.021
-
Improving Delivery of a Biomaterial Payload in Myocardial Infarction. Circ Cardiovasc Interv. 2016 10; 9(10).
Score: 0.021
-
Assessment of Cardiac Function--Basic Principles and Approaches. Compr Physiol. 2015 Sep 20; 5(4):1911-46.
Score: 0.020
-
Fate Versus Flow: Wall Shear Stress in the Aortopathy Associated With Bicuspid Aortic Valves. J Am Coll Cardiol. 2015 Aug 25; 66(8):901-4.
Score: 0.019
-
Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol. 2014 Sep 01; 307(5):H752-61.
Score: 0.018
-
Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014 Jul 01; 90(1):7-15.
Score: 0.018
-
Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014 Apr 25; 114(9):1435-45.
Score: 0.018
-
Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol. 2014 May; 70:92-9.
Score: 0.017
-
Integrating the myocardial matrix into heart failure recognition and management. Circ Res. 2013 Aug 30; 113(6):725-38.
Score: 0.017
-
Preoperative steroid treatment does not improve markers of inflammation after cardiac surgery in neonates: results from a randomized trial. J Thorac Cardiovasc Surg. 2014 Mar; 147(3):902-8.
Score: 0.017
-
Localized targeting of biomaterials following myocardial infarction: a foundation to build on. Trends Cardiovasc Med. 2013 Nov; 23(8):301-11.
Score: 0.017
-
Biomarkers and heart disease: what is translational success? J Cardiovasc Transl Res. 2013 Aug; 6(4):447-8.
Score: 0.017
-
Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 04; 112(1):195-208.
Score: 0.016
-
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol. 2013 Mar 01; 304(5):C393-402.
Score: 0.016
-
Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg. 2013 Jan; 145(1):267-275, 277.e1-4; discussion 275-7.
Score: 0.016
-
Gene targeting in ischemic heart disease and failure: translational and clinical studies. Biochem Pharmacol. 2013 Jan 01; 85(1):1-11.
Score: 0.016
-
Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012 Jun; 18(6):487-92.
Score: 0.016
-
Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
Score: 0.015
-
Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin. 2012 Jan; 8(1):7-20.
Score: 0.015
-
Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2012 May; 143(5):1069-76.
Score: 0.015
-
Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 2011 Dec; 4(6):614-9.
Score: 0.015
-
Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation. 2011 Sep 13; 124(11 Suppl):S62-9.
Score: 0.015
-
Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
Score: 0.015
-
Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg. 2011 Dec; 142(6):1523-9.
Score: 0.014
-
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011 May; 4(3):246-56.
Score: 0.014
-
Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol. 2011; 73:47-68.
Score: 0.014
-
Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy. Eur J Heart Fail. 2011 Mar; 13(3):271-7.
Score: 0.014
-
Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy. Cardiol Young. 2011 Feb; 21(1):52-61.
Score: 0.014
-
Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem. 2010 Sep 24; 285(39):30316-27.
Score: 0.014
-
Amplified bioactive signaling and proteolytic enzymes following ischemia reperfusion and aging: remodeling pathways that are not like a fine wine. Circulation. 2010 Jul 27; 122(4):322-4.
Score: 0.014
-
Circulating matrix metalloproteinase levels after ventricular septal defect repair in infants. J Thorac Cardiovasc Surg. 2010 Dec; 140(6):1257-65.
Score: 0.014
-
Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery. Ann Thorac Surg. 2010 Jun; 89(6):1843-52; discussion 1852.
Score: 0.014
-
Pathophysiology of myocardial injury and remodeling: implications for molecular imaging. J Nucl Med. 2010 May 01; 51 Suppl 1:102S-106S.
Score: 0.013
-
Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics. J Thorac Cardiovasc Surg. 2010 Mar; 139(3):646-54.
Score: 0.013
-
Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail. 2009 Jul; 2(4):351-60.
Score: 0.013
-
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail. 2009 May; 2(3):262-71.
Score: 0.013
-
Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg. 2008 Nov; 86(5):1576-83.
Score: 0.012
-
Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation. 2008 Sep 30; 118(14 Suppl):S16-23.
Score: 0.012
-
Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1394-402.
Score: 0.012
-
Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass. J Cardiovasc Pharmacol. 2008 Apr; 51(4):418-23.
Score: 0.012
-
Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg. 2007 Oct; 105(4):949-62.
Score: 0.011
-
Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007 Oct; 87(4):1285-342.
Score: 0.011
-
Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy. Am J Physiol Cell Physiol. 2007 Oct; 293(4):C1362-73.
Score: 0.011
-
Selective endothelin-A receptor inhibition after cardiac surgery: a safety and feasibility study. Ann Thorac Surg. 2007 Jun; 83(6):2153-60; discussion 2161.
Score: 0.011
-
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006 Sep 05; 114(10):1020-7.
Score: 0.010
-
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006 Mar; 131(3):679-85.
Score: 0.010
-
Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006 Feb 15; 69(3):666-76.
Score: 0.010
-
From tadpole tails to transgenic mice: metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease. Cardiovasc Res. 2006 Feb 15; 69(3):559-61.
Score: 0.010
-
Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol. 2005 May; 20(3):211-6.
Score: 0.010
-
Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
Score: 0.009
-
Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 Mar; 129(3):584-90.
Score: 0.009
-
Disruptions and detours in the myocardial matrix highway and heart failure. Curr Heart Fail Rep. 2005 Mar; 2(1):10-7.
Score: 0.009
-
Cell-matrix signaling and thrombospondin: another link to myocardial matrix remodeling. Circ Res. 2004 Sep 03; 95(5):446-8.
Score: 0.009
-
The effects of leukocyte reduction on matrix metalloproteinase release in cardiopulmonary bypass. J Extra Corpor Technol. 2004 Jun; 36(2):185-90.
Score: 0.009
-
Myocyte contractility with caspase inhibition and simulated hyperkalemic cardioplegic arrest. Ann Thorac Surg. 2004 May; 77(5):1684-9; discussion 1689-90.
Score: 0.009
-
Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle. Eur Heart J. 2004 Apr; 25(8):631-3.
Score: 0.009
-
A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2004 Feb; 18(1):25-9.
Score: 0.009
-
Effects of leukocyte depletion filters on matrix metalloproteinase activation in an extracorporeal circulation circuit. J Extra Corpor Technol. 2003 Jun; 35(2):139-42.
Score: 0.008
-
Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol. 2003 May; 35(5):539-48.
Score: 0.008
-
Extracellular matrix remodeling following myocardial injury. Ann Med. 2003; 35(5):316-26.
Score: 0.008
-
Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2002 Dec 18; 40(12):2165-73.
Score: 0.008
-
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002 Dec; 8(6):390-8.
Score: 0.008
-
Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail. 2002 Dec; 8(6 Suppl):S332-8.
Score: 0.008
-
The extracellular matrix: summation. J Card Fail. 2002 Dec; 8(6 Suppl):S349-50.
Score: 0.008
-
Interpretable machine learning predicts cardiac resynchronization therapy responses from personalized biochemical and biomechanical features. BMC Med Inform Decis Mak. 2022 10 31; 22(1):282.
Score: 0.008
-
Effects of adrenomedullin on human myocyte contractile function and beta-adrenergic response. J Cardiovasc Pharmacol Ther. 2002 Oct; 7(4):235-40.
Score: 0.008
-
Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002 Mar 22; 90(5):520-30.
Score: 0.008
-
Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers. Am J Physiol Heart Circ Physiol. 2022 05 01; 322(5):H798-H805.
Score: 0.008
-
Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002 Mar; 53(4):822-30.
Score: 0.008
-
The Effects of Regular Exercise on Circulating Cardiovascular-related MicroRNAs. Sci Rep. 2019 05 17; 9(1):7527.
Score: 0.006
-
Plasma matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs and aging and lifelong exercise adaptations in ventricular and arterial stiffness. Exp Gerontol. 2019 08; 123:36-44.
Score: 0.006
-
Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater. 2014 Jun; 13(6):653-61.
Score: 0.004
-
Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
Score: 0.004
-
Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. 2013 May; 465(5):687-97.
Score: 0.004
-
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res. 2012 Jun 22; 111(1):131-50.
Score: 0.004
-
Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg. 2012 Feb; 93(2):457-63.
Score: 0.004
-
Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet. 2011 Dec; 4(6):605-13.
Score: 0.004
-
Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
Score: 0.003
-
Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol. 2010 Jul; 134(1):23-30.
Score: 0.003
-
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010 May 04; 121(17):1912-25.
Score: 0.003
-
Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg. 2010 Apr; 139(4):984-90; discussion 990.
Score: 0.003
-
SmartDelay determined AV optimization: a comparison of AV delay methods used in cardiac resynchronization therapy (SMART-AV): rationale and design. Pacing Clin Electrophysiol. 2010 Jan; 33(1):54-63.
Score: 0.003
-
Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res. 2009; 46(2):119-37.
Score: 0.003
-
Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg. 2008 Nov; 136(5):1123-30.
Score: 0.003
-
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail. 2008 Feb; 10(2):125-8.
Score: 0.003
-
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
Score: 0.003
-
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007 Apr; 133(4):1028-36.
Score: 0.003
-
Proteinase systems and thoracic aortic aneurysm progression. J Surg Res. 2007 May 15; 139(2):292-307.
Score: 0.003
-
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 2006 Jul 04; 114(1 Suppl):I365-70.
Score: 0.003
-
Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
Score: 0.003
-
Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
Score: 0.002
-
Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation. 2004 Oct 05; 110(14):e333-6.
Score: 0.002
-
Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol. 2004 Oct; 37(4):801-11.
Score: 0.002